OncoMatch/Clinical Trials/NCT06114004
Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)
Is NCT06114004 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Selinexor 20 MG and Gemcitabine for sarcoma,soft tissue.
Treatment: Selinexor 20 MG · Gemcitabine — Phase I-II, non-randomized, single-arm, open-label, multicenter, international clinical trial. Patients with advanced soft-tissue sarcoma (leiomyosarcoma or malignant peripheral nerve sheath tumor) will receive selinexor in combination with gemcitabine.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Sarcoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: systemic therapy — advanced disease
Patients have previously received at least one previous line of systemic therapy.
Cannot have received: XPO1 inhibitor (selinexor)
Prior selinexor or another XPO1 inhibitor treatment.
Cannot have received: gemcitabine-containing treatment (gemcitabine)
Administration of a previous gemcitabine-containing treatment.
Cannot have received: systemic therapy
Three or more systemic treatment lines (including both chemotherapy and targeted therapy) for advanced disease (localized unresectable or metastatic).
Cannot have received: anti-cancer therapy or investigational product
Patients who have received any other anti-cancer therapy or investigational product in the last 21 days prior to enrollment.
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1,500/mm³; Platelet count ≥ 100,000/mm³; Hgb not specified
Kidney function
Creatinine ≤ 1.5 mg/dL
Liver function
Bilirubin ≤ 1.5 mg/dL; AST and ALT ≤ 2.5 times upper limit of normal
Cardiac function
Left ventricular ejection fraction ≥ 50% by echocardiogram or MUGA scan
Adequate hepatic, renal, cardiac, and hematologic function. Laboratory tests as follows: Absolute neutrophil count ≥ 1,500/mm³; Platelet count ≥ 100,000/mm³; Bilirubin ≤ 1.5 mg/dL; AST and ALT ≤ 2.5 times upper limit of normal; Creatinine ≤ 1.5 mg/dL. Left ventricular ejection fraction ≥ 50% by echocardiogram or MUGA scan.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06114004 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior XPO1 inhibitor, gemcitabine-containing treatment, systemic therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages